1/11/2018
`
`Meda has settled the U.S. Astelin® patent litigation with Apotex Stockholm Stock Exchange:MEDA A
`
`Meda has settled the U.S. Astelin® patent litigation with
`Apotex
`
`April 21, 2008 03:02 ET | Source: Meda AB
`
`Meda has settled the U.S. Astelin® patent litigation with Apotex
`
`Meda, through its wholly owned U.S. subsidiary, Meda Pharmaceuticals Inc., has
`entered into a settlement agreement with Apotex Inc. and Apotex Corp. (hereafter
`Apotex) that resolves the U.S. patent litigation between the companies regarding
`Apotex's proposed generic versions of Astelin® and Optivar®.
`Astelin® (azelastine hydrochloride nasal spray) is used for treatment of
`allergic and non-allergic rhinitis and Optivar® (azelastine hydrochloride
`ophthalmic solution) is used for treatment of allergic conjunctivitis. These
`products are protected in the U.S. by a patent that expires on 1 November 2010,
`with paediatric exclusivity extending until 1 May 2011.
`
`The settlement agreement resolves patent infringement actions filed by Meda
`after Apotex's submission of ANDAs (Abbreviated New Drug Applications) to the
`U.S. FDA (Food & Drug Administration) for generic versions of Astelin® and
`Optivar® in 2006 and 2007, respectively. Under the settlement agreement, Apotex
`admits infringement of Meda's patent. Given the settlement agreement, the
`parties will jointly request that scheduled trials regarding Apotex's proposed
`generic version of Astelin® in May 2008 and proposed generic version of Optivar®
`in February 2009 be adjourned and the actions closed.
`
`The settlement agreement allows Apotex to launch a generic version of Astelin®,
`under a license from Meda, on 1 March 2010. In such case, Apotex will pay 32.5%
`of their net sales of this product to Meda until 1 February 2011. The agreement
`also allows Apotex to launch a generic version of Optivar®, under license from
`Meda, on 1 December 2009, without further payments to Meda.
`
`“This settlement agreement brings clarity to Meda's intellectual property rights
`on the U.S. patent for Astelin® and Optivar®,” said Anders Lönner, CEO Meda.
`
`In compliance with U.S. law, the settlement agreement will be submitted to the
`U.S. Federal Trade Commission and Department of Justice and is subject to their
`review.
`
`For more information, please contact:
`
`Anders Larnholt, Investor Relations, tel. +46 8 630 19 62, +46 709 458 878
`anders.larnholt@meda.se
`
`MEDA AB (publ) is an international specialty pharma company that concentrates on
`marketing and market-adapted product development. Acquisitions and long-term
`partnerships are fundamental factors that drive the company's strategy. Meda is
`represented with own organisations in 26 countries and with more than 1 500
`employees within marketing and sales. Meda's products are sold in approximately
`120 countries world-wide. The Meda share is listed under Large Cap on the OMX
`Nordic Stock Exchange. Find out more, visit www.meda.se.
`
`Exhibit 1060
`IPR2017-00807
`ARGENTUM
`
`https://globenewswire.com/news-release/2008/04/21/56156/0/en/Meda-has-settled-the-U-S-Astelin-patent-litigation-with-Apotex.html
`
`1/2
`
`000001
`
`

`

`Meda has settled the U.S. Astelin® patent litigation with Apotex Stockholm Stock Exchange:MEDA A
`1/11/2018
`Newswire Distribution Network & Management
`
`Home
`Newsroom
`RSS Feeds
`Legal
`Contact Us
`
`ABOUT US
`GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks,
`specializing in the delivery of corporate press releases financial disclosures and multimedia content to
`the media, investment community, individual investors and the general public.
`
`© 2018 GlobeNewswire, Inc. All Rights Reserved.
`
`https://globenewswire.com/news-release/2008/04/21/56156/0/en/Meda-has-settled-the-U-S-Astelin-patent-litigation-with-Apotex.html
`
`2/2
`
`000002
`
`